Distinct in vitro Complement Activation by Various Intravenous Iron Preparations by Hempel, Julia Cordelia et al.
  
 University of Groningen
Distinct in vitro Complement Activation by Various Intravenous Iron Preparations
Hempel, Julia Cordelia; Poppelaars, Felix; da Costa, Mariana Gaya; Franssen, Casper F. M.;
de Vlaam, Thomas P G; Daha, Mohamed R.; Berger, Stefan P.; Seelen, Marc A. J.; Gaillard,
Carlo A. J. M.
Published in:
American Journal of Nephrology
DOI:
10.1159/000451060
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Hempel, J. C., Poppelaars, F., da Costa, M. G., Franssen, C. F. M., de Vlaam, T. P. G., Daha, M. R., ...
Gaillard, C. A. J. M. (2017). Distinct in vitro Complement Activation by Various Intravenous Iron
Preparations. American Journal of Nephrology, 45(1), 49-59. https://doi.org/10.1159/000451060
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
E-Mail karger@karger.com
 Original Report: Laboratory Investigation 
 Am J Nephrol 2017;45:49–59 
 DOI: 10.1159/000451060 
 Distinct in vitro Complement Activation 
by Various Intravenous Iron Preparations 
 Julia Cordelia Hempel a    Felix Poppelaars a    Mariana Gaya da Costa a    
Casper F.M. Franssen a    Thomas P.G. de Vlaam a    Mohamed R. Daha a, b    
Stefan P. Berger a    Marc A.J. Seelen a    Carlo A.J.M. Gaillard a  
 a  Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center 
Groningen,  Groningen , and  b  Department of Nephrology, University of Leiden, Leiden University Medical Center, 
 Leiden , The Netherlands 
tran significantly induced complement activation in the 
blood of healthy volunteers and HD patients. Furthermore, 
in the ex-vivo assay, ferric carboxymaltose and iron sucrose 
only caused significant complement activation in the blood 
of HD patients. No in-vitro or ex-vivo complement activation 
was found for ferumoxytol and iron isomaltoside. IV iron 
therapy with ferric carboxymaltose in HD patients did 
not lead to significant in-vivo complement activation. 
 Conclusion: This study provides evidence that iron dextran 
and ferric carboxymaltose have complement-activating ca-
pacities in-vitro, and hypersensitivity reactions to these 
drugs could be CARPA-mediated.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 
 Introduction 
 A majority of patients with chronic kidney disease 
(CKD) receive intravenous (IV) iron for the treatment of 
anemia  [1] . However, controversy exists regarding the 
safety of IV iron preparations since hypersensitivity reac-
tions have been reported for all iron drugs  [2] . Although 
these reactions appear sporadic, they can be acute and life 
 Key Words 
 Intravenous iron · Complement activation related pseudo 
allergy · Hypersensitivity reaction · Complement activation · 
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 Abstract 
 Background: Intravenous (IV) iron preparations are widely 
used in the treatment of anemia in patients undergoing he-
modialysis (HD). All IV iron preparations carry a risk of caus-
ing hypersensitivity reactions. However, the pathophysio-
logical mechanism is poorly understood. We hypothesize 
that a relevant number of these reactions are mediated by 
complement activation, resulting in a pseudo-anaphylactic 
clinical picture known as complement activation-related 
pseudo allergy (CARPA).  Methods: First, the in-vitro comple-
ment-activating capacity was determined for 5 commonly 
used IV iron preparations using functional complement as-
says for the 3 pathways. Additionally, the preparations were 
tested in an ex-vivo model using the whole blood of healthy 
volunteers and HD patients. Lastly, in-vivo complement ac-
tivation was tested for one preparation in HD patients. 
 Results: In the in-vitro assays, iron dextran, and ferric car-
boxymaltose caused complement activation, which was 
only possible under alternative pathway conditions. Iron su-
crose may interact with complement proteins, but did not 
activate complement in-vitro. In the ex-vivo assay, iron dex-
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threatening. The exact frequency of the hypersensitivity 
reactions is unknown. This is attributed to a lack of data, 
due to underreporting and differential reporting  [3] .
 The underlying mechanism of reactions due to the hy-
persensitivity of IV iron remains unclear. However, elu-
cidating the pathophysiology is critical to improve pre-
diction, prevention and management of these adverse 
events. In contrast to the immunoglobulin E (IgE)-medi-
ated anaphylaxis observed in older compounds of IV 
iron, hypersensitivity reaction due to new IV iron prepa-
rations are thought to result from complement activa-
tion-related pseudo allergy (CARPA)  [4, 5] . Nonetheless, 
this has not been tested systematically. CARPA is an ad-
verse event seen after the administration of monoclonal 
antibodies, intravenously administered drugs and 
nanoparticle-containing drugs  [4, 5] . CARPA was postu-
lated since all available preparations consist of iron-car-
bohydrate nanoparticles  [6] .
 Activation of the complement system occurs via 
3 pathways: the classical pathway (CP), the lectin pathway 
(LP) and the alternative pathway (AP). The CP is acti-
vated by antibody–antigen complexes, the LP by carbo-
hydrates and the AP by microbial surfaces. This results in 
the formation of the C3- and C5-convertases and the gen-
eration of anaphylatoxins. Subsequently, activation of the 
terminal pathway leads to the formation of the membrane 
attack complex (C5b-9)  [7] . In CARPA, such a cascade is 
initiated predominantly by the generation of comple-
ment activation products, leading to the stimulation of 
mast cells and basophil granulocytes resulting in secre-
tion products, which cause various responses in effector 
cells such as platelets, endothelial cells and smooth mus-
cle cells. Clinically, these processes may give rise to bron-
chospasm, laryngeal edema, tachycardia, hypo- or hyper-
tension and hypoxia  [5] .
 The aim of this study was to determine the effect of 
5 currently available IV iron preparations on the comple-
ment system. By evaluating different IV iron drugs in an 
in-vitro and ex-vivo model for complement activation, we 
intended to test for the probability of CARPA by IV iron 
drugs. Lastly, in-vivo complement activation was tested for 
one IV iron preparation in hemodialysis (HD) patients.
 Materials and Methods 
 2.1 Subjects 
 We recruited 2 groups:
 • Control subjects (5–10 per experiment, as indicated below). 
 • Patients on maintenance HD (n = 8). During one dialysis 
 session, blood samples were taken at 0, 120 and 240 min dur-
ing dialysis. Patients received 100 mg/2 ml ferric carboxy-
maltose (Ferinject © ) IV over 1 h at 120 min into the dialysis 
session. 
 2.2 Reagents 
 Iron sucrose (Venofer © ) and ferric carboxymaltose  (Ferinject © ) 
were purchased from Vifor Nederland, Breda, The Netherlands; 
ferumoxytol (Rienso © ) from Takeda Nederland, Hoofddorp, The 
Netherlands; low molecular weight iron dextran (CosmoFer © ) and 
iron isomaltoside 1000 (Monofer © ) from Cablon Medical,  Leusden, 
The Netherlands.
 For the whole blood experiments, lepirudin (Refludan © , 
Hoechst, Frankfurt am Main, Germany) was used as anticoagu-
lant.
 2.3 Normal Human Serum 
 Blood was taken from 10 healthy volunteers and directly stored 
on ice. Samples were centrifuged, then pooled and stored at –80  °  C 
until further analysis.
 2.4 Complement Pathway Activity in Human Serum 
 Functional assays were used to allow quantification of com-
plement activation via the CP, the LP and AP in human serum. 
These assays were previously described  [8] . In brief, 96-well 
plates were coated overnight with human immunoglobulin M for 
the CP, mannan for the LP or lipopolysaccharide (LPS) for the 
AP. Plates were washed 3 times after each step with PBS contain-
ing 0.05% Tween-20. Plates were blocked with 1% bovine serum 
albumin (BSA) in PBS for 1 h at 37   °   C. Serum was diluted in 
 gelatin veronal buffer (GVB) buffer adapted specifically for each 
pathway. For the CP and LP, serum was diluted in GVB with 
Ca 2+ –Mg 2+ . For the AP, serum was diluted in GVB with magne-
sium only. After 1 h at 37  °  C, deposition the of properdin, C4, C3 
or C5b-9 was detected using rabbit anti-human properdin 
 (obtained from the laboratory of Nephrology, Leiden, The 
 Netherlands), mouse anti-human C4 (obtained from the labora-
tory of Nephrology, Leiden, The Netherlands), RFK22 (anti-hu-
man C3, obtained from the laboratory of Nephrology, Leiden, 
The Netherlands) and AE11 (anti-human C5b-9, DAKO, 
 Glostrup, Denmark), respectively. Binding of antibodies was de-
tected using the appropriate primary and secondary antibody. 
For visualization, TMB and H 2 SO 4 were added before the absorp-
tion was measured at 450 nm.
 Prior to incubation on the enzyme linked immunosorbent as-
say (ELISA) plate, all serum samples were pre-incubated at 37   °   C 
for 30 min with iron in a dose ranging from 0.0625 to 0.5 mg/ml. 
Next, samples were further diluted to the final concentration with 
the appropriate buffer.
 2.5 Complement Activation Assays by IV Iron 
 For the complement activation assay, iron preparations or BSA 
were coated overnight on a 96-well plate followed by blocking with 
1% BSA/PBS at 37   °   C for 1 h. The wells were exposed to pooled 
human serum diluted in adapted GVB (see 2.3) or with ethylene-
diaminetetraacetic acid (EDTA; 20 m M ) for 1 h at 37  °  C. The plate 
was then incubated with antibodies against properdin, C3 or 
 C5b-9 (see 2.3). Detection was completed using appropriate pri-
mary and secondary antibody. The plate was washed with PBS 
Tween-20 (0.05%) after each step. Visualization was similar as de-
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 2.6 Complement Pathway Activity in Human Whole Blood 
 The experimental set-up has previously been described  [9] . In 
short, blood was drawn in LPS-free tube with 50 μg/ml lepirudin. 
Whole blood was then incubated for 0 or 90 min at 37   °  C with IV 
iron (0.5 mg/ml ferrous iron) while continuously rotated. PBS was 
added to the negative controls. The reaction was stopped with 
EDTA (final concentration of 20 m M ). Samples were then centri-
fuged and plasma was stored at –80  °  C until further analysis.
 2.7 Quantification of the Antigenic Levels of C1q, C3d, C3 
Mannose-Binding Lectin, Properdin and C5b-9 
 The ELISA for C1q, C3d, C3 mannose-binding lectin (MBL), 
properdin, and C5b-9 were performed as described previously 
 [10–12] .
 2.8 Statistics 
 Statistical analyzes were performed using BM SPSS Statistics 
Version 22 and p values <0.05 were considered statistically sig-
nificant. The Kruskal–Wallis test and Mann–Whitney U test were 
used to assess differences between groups of non-parametric data 
and one-way analysis of variance and t test for normally distrib-
uted data. If needed, data was in-transformed for normality.
 2.9 Ethics 
 All participants gave informed consent. The Medical Ethical 
Committee of the University Medical Center Groningen has re-
viewed the study design and it was confirmed that an official ap-
proval of this study by the committee is not required since the 
 Medical Research Involving Human Subjects Act (WMO) does 
not apply.
 Results 
 3.1 In-vitro effect of IV iron preparations on 
complement activity 
 The interaction of the different IV iron drugs with 
complement was determined using functional comple-
ment assays for each pathway. Normal human serum 
(NHS) was pre-incubated with different IV iron drugs 
prior to the assay; subsequently, residual complement ac-
tivity was measured. In this assay, decreased residual ac-
tivity reflects either activation or inhibition of comple-
ment by the IV iron compound during the pre-incuba-
tion period.
 3.1.1 Decreased Residual Activity of the CP by Iron 
Sucrose 
 First, residual complement activity was tested for 
the CP after incubation with the IV iron drugs ( table 1 ). 
Iron sucrose was the only preparation that significantly 
reduced residual complement activity. Furthermore, 
the effect of iron sucrose on CP activity (p = 0.016) 
was dose-dependent ( fig. 1 ). At a concentration of 0.5 
mg/ml, iron sucrose reduced C4, C3 and C5b-9 deposi-
tion by 92, 88 and 96%, respectively (p < 0.001). For 
iron dextran, ferric carboxymaltose, iron isomaltoside 
Table 1.  Activation of complement components of the CP, LP and AP by IV iron drugs
Residual complement
activity1
IV iron preparations, %
control iron dextran ferric carboxy-maltose iron isomaltoside 
1000
ferumoxytol iron sucrose
CP 100±5.5 126.8±23.4 94.3±13.8 108.2±3.9 110.8±4.2 10.4±4.5***
LP 100±5.2 88±4.4 88.7±3.5 84.3±2.4 91.4±3.3 4.7±0.4***
AP 100±4.6 6.3±0.9*** 62.3±11.8* 75±14.5 89.2±16.5 80±16
Complement 
activation2
 IV iron preparations, %
positive 
contr ol
iron dextran ferric carboxy-maltose iron isomaltoside 
1000
ferumoxytol iron sucrose BSA
CP 100±0.5 2.9±0.1 2.5±0.1 2.5±0.1 3.0±0.1 3.0±0.0 2.9±0.1
LP 100±3.4 3.1±0.1 3.0±0.1 4.1±0.1 3.8±0.3 4.0±0.1 4.0±0.1
AP 100±8.1 138.5±5.5*** 122.2±10.9** 9.1±0.4 8.6±0.3 8.1±0.4 9.7±2.1
1 Pooled serum was pre-incubated with 0.5 mg/ml ferrous iron for 30 min at 37°C. PBS was used for the controls. The serum was 
then used in the functional assay for the CP, LP or AP to measure residual activity. Deposition of C5b-9 was used as readout and the 
amount obtained in the control was set at 100% 
2 Iron preparations were coated overnight on a 96-well plate. The wells were exposed to pooled human serum diluted in a buffer 
adapted specifically for each pathway. Deposition of C5b-9 was used as readout and the amount obtained in the positive control was 
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and ferumoxytol, there was no change in residual 
 complement activity, indicating low to no effect on 
the CP.
 3.1.2 Decreased residual activity of the LP by iron 
sucrose 
 Next, residual complement activity for the LP was as-
sessed ( table 1 ). Once again, iron sucrose significantly re-
duced residual complement activity in a dose-dependent 
manner (p < 0.001) indicating prominent activation of 
the LP during the pre-incubation period ( fig. 1 ). Deposi-
tion of C4, C3 and C5b-9 were lowered by 88, 95 and 95% 
at 0.5 mg/ml for iron sucrose (p < 0.001). For iron dex-
tran, ferric carboxymaltose, iron isomaltoside and feru-
moxytol, there was no change in residual complement ac-




























































































































































 Fig. 1. The dose-dependent decrease of residual activity of the CP, 
LP and AP by iron sucrose, iron dextran and ferric carboxymalt-
ose.  Pooled serum was pre-incubated with increasing concentra-
tions of intravenous iron (x-axis, log2 scale) for 30 min at 37°C. 
PBS was used for the controls. The serum was then used in the 
functional assay for the CP, LP and AP to measure residual activ-
ity. Deposition of C4, properdin, C3 and C5b-9 were used as read-
out and the amount obtained in the control was set at 100% (y-
axis). Data are shown as mean ± SEM of 3 experiments (* p < 0.05, 
** p < 0.01, *** p < 0.001).
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 3.1.3 Decreased Residual Activity of the AP by Iron 
Dextran and Ferric Carboxymaltose 
 Lastly, residual activity of the AP was analyzed 
 ( table 1 ). The addition of iron dextran and ferric carboxy-
maltose caused a significant reduction in residual com-
plement activity at the level of C5b-9 generation ( fig. 1 ). 
In accordance, pre-incubation with iron dextran and fer-
ric carboxymaltose resulted in a significant dose-depen-
dent reduction of residual complement activity at the lev-
el of properdin and C3 deposition (p < 0.01). For iron 
dextran, deposition of properdin, C3 and C5b-9 were 
lowered by 71, 85 and 94% at 0.5 mg/ml (p < 0.01) and 
lowered by 34, 24 and 30% at 0.5 mg/ml (p < 0.01) for 
ferric carboxymaltose, respectively. Ferumoxytol, iron 
sucrose and iron isomaltoside did not affect the comple-
ment activity of AP.
 3.2 In-vitro Testing of Complement Activation by IV 
Iron Drugs 
 Next, we investigated whether IV iron preparations 
can directly activate the complement system. In an 
 ELISA-based set-up, we immobilized the IV iron drugs 
on the plate and added NHS diluted in buffers that al-















































































































































































   
   
   
   
   
   
   
   
   







































































































































 Fig. 2.  a–e AP-mediated complement activation on iron dextran 
and ferric carboxymaltose. a ELISA wells were coated with iron 
dextran, ferric carboxymaltose at 50 μg and 1% BSA as negative 
control. Wells were blocked by 1% BSA/PBS for 60 min at 37°C. A 
fixed concentration of 15% pooled human serum diluted in GVB++ 
MgEGTA or EDTA was added to the wells with detection by mouse 
anti-human C5b-9 antibody. Data are shown as mean ± SEM of 3 
experiments. b Iron dextran and ferric carboxymaltose at various 
concentrations or 1% BSA were coated to the wells. All coated wells 
had 1% BSA/PBS added for 60 min at 37°C as a blocking agent. 
Fifteen percent pooled human serum diluted in GVB++ MgEGTA 
was added followed by detection using mouse anti-human C5b-9 
antibody. c–e Iron dextran and ferric carboxymaltose were coated 
at 50 μg and 1% BSA as negative control to the wells. The plate was 
blocked using 1% BSA/PBS at 37°C for 60 min. Increasing concen-
trations of pooled human serum diluted in GVB++ MgEGTA were 
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conditions, iron dextran and ferric carboxymaltose had 
the capacity to activate the AP. Ferumoxytol and iron 
isomaltoside showed no complement activation for all 
pathways ( table 1 ). In this set-up, iron sucrose failed to 
show complement activation for the LP or the CP.
 3.2.1 AP Activation by Iron Dextran and Ferric 
Carboxymaltose 
 We further determined conditions required for iron 
dextran and ferric carboxymaltose-mediated comple-
ment activation. An ELISA plate was coated with iron 
dextran, ferric carboxymaltose or BSA and then exposed 
to 15% pooled human serum diluted in either magnesium 
ethylene glycol tetraacetic acid (MgEGTA) or EDTA. 
Subsequently, C5b-9 deposition was assessed. Iron 
 dextran and ferric carboxymaltose coating caused strong 
C5b-9 depositions compared to BSA controls ( fig.  2 a). 
The addition of EDTA completely inhibited complement 
deposition. Hence, complement deposition was the result 
of calcium- and magnesium-dependent complement ac-
tivation. The degree of complement activation was de-
pendent on the concentration of iron dextran and ferric 
carboxymaltose immobilized on the plate ( fig. 2 b). Fur-
thermore, we titrated NHS in MgEGTA and showed that 
C5b-9 depositions were dose-dependent when compared 
to the negative control, BSA ( fig.  2 c). Lastly, we tested 
whether AP activation also involves deposition of other 
complement components of the AP. We found that simi-
lar to C5b-9 deposition, C3 ( fig. 2 d) and properdin depo-
sition ( fig.  2 e) occurred in a dose-dependent manner, 
while no C4 deposition was observed (data not shown). 
Altogether, these results show that dextran and ferric car-
boxymaltose-mediated complement activation is only 
possible under AP conditions.
 3.3 Ex-vivo Analysis of the Effect of IV Iron Drugs on 
Complement Activation in Healthy Volunteers 
 The effect of IV iron drugs on fluid phase complement 
activation was determined by incubating IV iron prepara-
tion (0.5 mg/ml ferrous iron) for 90 min in human whole 
blood. Subsequently, complement activation in the sam-
ples was determined by measuring soluble C5b-9  (sC5b-9) 
levels. Increased sC5b-9 levels demonstrate complement 
activation. Additionally, properdin, MBL and C1q levels 
were measured to determine which pathway was involved.
 3.3.1 Ex-vivo Terminal Pathway Complement 
Activation by Iron Dextran 
 The addition of iron dextran to whole blood samples 
of healthy volunteers led to the activation of vast terminal 
pathways ( fig. 3 a). Levels of sC5-b9 were 13-fold higher 
than in the controls (p < 0.001). Incubation with iron su-
crose, ferric carboxymaltose, iron isomaltoside or feru-
moxytol did not lead to significant complement activa-
tion.
 3.3.2 Ex-vivo Complement Activation by Iron 
Dextran Is Mediated via the AP 
 In order to determine which complement pathway was 
activated, C1q, MBL and properdin were measured at 
0 and 90 min. For iron dextran, a significant decrease in 
properdin concentration of 42% was found compared to 
control (p = 0.032). The concentration of C1q and MBL 
remained largely unchanged ( fig. 3 b). No significant al-
terations of in C1q, MBL and properdin concentration 
were found for iron sucrose, ferric carboxymaltose, iron 
isomaltoside and ferumoxytol.
 3.4 Effect of IV Iron Drugs on Complement in Whole 
Blood from HD Patients 
 Next, we analyzed whether the observed effects of iron 
dextran can be extrapolated from control subjects with-
out CKD onto HD patients with severe CKD, and wheth-
er other iron preparations induce complement activation 
similar to iron dextran.
 3.4.1 Ex-vivo Terminal Pathway Complement 
Activation by Iron Dextran 
 Similar to healthy controls, iron dextran led to signifi-
cant complement activation in whole blood from HD pa-
tients (p < 0.001), indicated by the marked sC5b-9 gen-
eration ( fig. 3 c). Furthermore, ferric carboxymaltose and 
iron sucrose led to significant complement activation in 
HD whole blood but not in healthy controls. However, 
the complement activation by ferric carboxymaltose and 
iron sucrose was 2- to 3-fold lower than it was in iron 
dextran. Iron isomaltoside or ferumoxytol did not lead to 
significant complement activation.
 3.5 No in-vivo Complement Activation by Current IV 
Iron Treatment in HD Patients 
 Lastly, we checked if the current IV iron therapy, used 
at our dialysis unit, leads to in-vivo complement activa-
tion in HD patients ( fig. 3 d, e). Prior to iron therapy, all 
patients displayed strong complement activation within 
the first 120 min. The sC5b-9 levels ( fig.  3 d) increased 
from 109 ng/ml (interquartile range (IQR) 85–122) to 247 
ng/ml (IQR 211–274), while the C3d/C3-ratio ( fig. 3 e) al-
most doubled from 7.68 (IQR 5.52–9.92) to 13.04 (IQR 
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 Fig. 3.  a–e The ex-vivo effect of iron preparations and in-vivo effect 
of ferric carboxymaltose on complement activation.  Whole blood 
was incubated with 0.5 mg/ml of iron dextran, Iron sucrose, ferric 
carboxymaltose, iron isomaltoside and ferumoxytol (x-axis) for 90 
min at 37°C. PBS was used for the controls. a Concentration of 
sC5b-9 was determined in plasma from healthy controls and used as 
read-out for complement activation (y-axis). Data are mean and 
SEM of 5 experiments using different donors each time. b The con-
centration of C1q, MBL and properdin was determined in samples 
from healthy controls with 0.5 mg/ml of iron dextran at 0 and 90 
min. The difference in concentration was calculated by dividing the 
concentration at 90 min, by the concentration at 0 min and then 
minus 100% (y-axis). c Concentration of sC5b-9 was determined in 
plasma from HD patients (y-axis). Data are mean and SEM of 8 ex-
periments using different donors each time. d sC5-9 levels and e 
C3d/C3-ratio were determined in HD patients during one dialysis 
session, in which they received 100 mg of ferric carboxymaltose at 
120 min into the dialysis session. Data are mean and SEM of 8 sub-
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 carboxymaltose intravenously throughout the following 
1 h at 120 min into the dialysis session. At the end of 
the  dialysis, complement levels remained higher than 
baseline but did not increase significantly compared to 
levels at 120 min. Median sC5b-9 levels at 240 min were 
252 ng/ml (IQR 188–264), while C3d/C3-ratio were 15.22 
(IQR 11.40–16.29).
 Discussion 
 Current EMA-approved IV iron drugs have markedly 
better safety profiles than the traditional IV iron com-
pounds. However, hypersensitivity reactions still occur 
and have led to controversy regarding the safety and the 
risk–benefit ratio of these preparations  [2] . Unlike the 
IgE-mediated reactions by older IV iron compounds, the 
majority of hypersensitivity reactions by the new IV iron 
preparations are thought to be caused by CARPA  [4–6] . 
The results of our study are the first, to our knowledge, to 
support this hypothesis by demonstrating the capacity of 
several IV iron preparations to activate complement in 
in-vitro and ex-vivo models using blood samples of 
healthy volunteers and HD patients.
 Initially, an in-vitro assay was used to investigate a 
possible interaction between IV iron and complement in 
serum. In this set-up, interaction (binding) and comple-
ment activation cannot be distinguished. During pre-in-
cubation, the IV iron drug reacts with the complement 
system. If the IV iron preparation activates complement, 
this consequently leads to decreased residual comple-
ment activity and therefore the deposition on the ELISA 
plate will be reduced. However, if IV iron binds the com-
plement proteins, then this effect will also reduce comple-
ment deposition as the drug is only diluted but not re-
moved after the pre-incubation step.
 In order to distinguish between true IV iron-mediated 
activation and other forms of interaction, ELISA plates 
were coated with different concentrations of IV iron prep-
arations and fixed concentrations of NHS were added. 
Complement activation was increased in a dose-depen-
dent manner by iron dextran and ferric carboxymaltose 
under AP-specific conditions. Combining these results, 
we can conclude that the reduced complement deposition 
after incubation with iron dextran and ferric carboxymalt-
ose in NHS in the functional assays was indeed due to 
complement activation. However, for iron sucrose, we 
have to consider an alternative explanation such as a direct 
effect of iron sucrose on C2, C4 or the serine proteases.
 We also tested the capacity of each drug to activate 
complement in an ex-vivo model. By incubating whole 
blood with iron, the preparations were not only exposed 
to serum components but also to blood cells and mem-
brane-bound complement regulatory factors. In line with 
the previous in-vitro experiments, iron dextran induced 
significant complement activation, while, surprisingly, 
ferric carboxymaltose did not. This might be because the 
functional assays measure complement deposition on a 
plate and thereby test solid phase activation while the 
whole blood model tests fluid phase activation by mea-
suring soluble complement activation products. A similar 
discrepancy has been found for LPS and IgA  [8, 13] . Fur-
thermore, the whole blood model and the functional as-
says differ in sensitivity. While coating with the iron prep-
aration and exposing it to NHS serum is a very sensitive 
test, the whole blood model does not involve dilution of 
the blood sample and is, therefore, a more physiological 
approach.
 Subsequently, we analyzed the effect of IV iron in a 
group of HD patients who are regularly receiving IV iron. 
In the ex-vivo experiments, whole blood from HD pa-
tients showed similar activation trends as whole blood 
from healthy volunteers. In both groups, iron dextran 
caused a significant increase in sC5b-9 generation. How-
ever, the overall complement activation was lower com-
pared to healthy volunteers. This can be considered a sign 
of pre-existing chronic complement activation, which is 
well described in HD patients  [11, 12, 14] . Concordantly, 
in our in-vivo experiments, elevated C3d/C3 ratio and 
C5b-9 serum levels were measured in blood samples tak-
en from these patients prior to dialysis.
 The IV infusion of ferric carboxymaltose did not lead 
to significant additional complement activation in HD 
patients. Both, sC5b-9 levels as well as the C3d/C3 ratio 
rose during the first half of the dialysis session and then 
remained consistently elevated from the start of the IV 
iron administration till the end of the HD session. While 
these measurements were performed in a small patient 
group, the results are in line with the ex-vivo findings, 
which did not indicate strong complement activation ca-
pacity for ferric carboxymaltose. Moreover, the slow ad-
ministration as a continuous infusion over 1 h reduces 
the risk of massive complement activation  [5, 15] . Lastly, 
vast complement activation and subsequently relative de-
pletion of complement factors has taken place during the 
first half of the HD session. We would therefore expect to 
see more complement activation in non-dialysis CKD 
patients after IV iron. In addition, we would hypothesize 
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tivation than slow administration. This is supported by 
previous studies, showing that the rate of infusion is cru-
cial for both the risk of hypersensitivity reactions and 
complement activation  [5, 15, 16] . As none of our pa-
tients are currently treated with iron dextran, we were 
unfortunately not able to test the complement activating 
properties of this iron preparation in-vivo. To further un-
ravel the effects of different iron preparations in-vivo, a 
trial comparing the ex-vivo and in-vivo effects of differ-
ent IV iron drugs in various patient populations would be 
needed. Nonetheless, since these trials will not be able to 
observe and compare the very rare clinical severe adverse 
events, data of observational cohorts including adequate 
sampling need to be gathered. In addition, further in-vi-
tro studies may help to better understand the mechanism 
behind hypersensitivity reactions by IV iron prepara-
tions.
 Clear guidelines exist regarding the maximum dose 
and minimal duration of administration per IV iron drug. 
For iron dextran and iron sucrose, the recommended 
dose is 100–200 mg, to be administered intravenously 
over 2–5 min for 5–10 consecutive HD sessions. Consid-
ering an average post-dialysis blood volume of 3,755 ± 
941 ml , final blood concentrations would vary between 42 
and 71 μg/ml. Other IV iron drugs are given in higher 
doses or administrated more rapidly, resulting in much 
higher local concentrations at the site of injection than 
concentrations measured in the peripheral blood [16, 17] . 
In addition to that, Geisser and Burckhardt  [18] found 
higher IV iron blood concentrations  after repetitive dos-
ing. Thus, concentrations chosen for the experiments are 
considered physiologically reasonable.
 A limitation of our study is the extrapolating of our 
findings into the clinical setting. Hypersensitivity reac-
tions to IV iron are rare and not in line with the comple-
ment activation seen in the in-vitro and ex-vivo results. 
Thus, an extremely important question that remains to be 
answered is concerning the difference in frequency of 
clinically observed adverse events and the frequency and 
magnitude of complement activation in our in-vitro ex-
periments. Factors such as route and rate of administra-
tion and patient characteristic (conditions of pre-existent 
complement activation) determine the magnitude of 
complement activation. However, mere activation of the 
complement system is not sufficient to cause CARPA, but 
it is a crucial first step in this reaction. In addition, beyond 
the acute effects, it has been hypothesized that repetitive 
complement activation, inflammation and oxidative 
stress may cause endothelial dysfunction and vascular re-
modeling. Indeed, in an observational study, Michael et 
al.  [19] report an 18% increase in mortality in HD patients 
receiving high doses of IV iron. However, due to the ob-
servational study design, no conclusion could be drawn 
regarding the causal relation between IV iron and mortal-
ity.
 Previous studies defined a 5- to 10-fold increase of 
complement activation as a realistic predictor for clinical 
reactions  [20] . Given this information, it can be assumed 
that iron dextran carries a risk of causing CARPA-medi-
ated hypersensitivity reactions. In accordance with our 
findings, it has been shown that dextran-coated mag-
netic iron nanoparticles activate the complement system 
via the AP. These agents are used as an MRI contrast 
agent and are able to cause severe hypersensitivity reac-
tions in patients. The chemical structure of the iron dex-
tran preparation is similar to this contrast agent  [21] . We 
hypothesize that the iron–carbohydrate nanoparti-
cles have complement-activating properties and not the 
iron itself, since ferric chloride did not cause significant 
complement activation (data not shown). In addition, 
there are several clinical studies stating the higher risk of 
serious adverse events after the administration of iron 
dextran formulations [19, 22] . Recently, Wang et al. in-
vestigated the risk of adverse events among the different 
IV iron drugs. A 3 times higher rate of adverse events 
was found for iron dextran compared to other IV iron. 
Also, more anaphylactic reactions were seen after the 
first administration of IV iron compared to repeated ad-
ministration  [23] . This phenomenon is in line with our 
results and the description of CARPA  [24] . Ferric 
 carboxymaltose also showed complement activating ca-
pacity and could shift the regulatory balance in predis-
posed individuals toward unregulated complement acti-
vation.
 In conclusion, the present study shows that different 
IV iron formulations have the in-vitro capacity to acti-
vate complement in healthy individuals as well as in 
HD patients undergoing long-term IV iron treatment. 
The major finding of this study is that iron dextran sig-
nificantly activates complement via the AP in-vitro and 
ex-vivo. In addition, ferric carboxymaltose also activat-
ed complement in-vitro via the AP. Furthermore, iron 
sucrose may interact with complement proteins of the 
LP and CP, but did not activate complement. Notably, 
slow infusion of ferric carboxymaltose during HD did 
not lead to additional complement activation. Our re-
sults indicate that current guidelines are efficient at 
avoiding CARPA by IV iron and explain why these 
routinely administered drugs show a limited number of 
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edge, to provide proof of concept of complement acti-
vation by IV iron and therefore provide new insights 
into the pathophysiological mechanism for a well-de-
scribed adverse reaction to IV iron. Mere activation of 
the complement system is not sufficient to cause CAR-
PA, but it is a crucial first step in this reaction. Further-
more, long-term complement activation is known to 
cause free radical generation and accelerate arterioscle-
rosis. These findings warrant further translational stud-
ies in HD and iron naïve patients in order to gain new 
insights into the pathophysiological mechanism of 
these clinical adverse events and to develop a safer 
treatment.
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